CERo Therapeutics (NASDAQ:CERO) versus Tonix Pharmaceuticals (NASDAQ:TNXP) Financial Contrast

Tonix Pharmaceuticals (NASDAQ:TNXP) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility and Risk

Tonix Pharmaceuticals has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Tonix Pharmaceuticals and CERo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1	0	1	1	2.67
CERo Therapeutics	1	2	0	0	1.67

Tonix Pharmaceuticals presently has a consensus price target of $22.00, indicating a potential upside of 81.07%. CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 142,080.09%. Given CERo Therapeutics’ higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than Tonix Pharmaceuticals.

Profitability

This table compares Tonix Pharmaceuticals and CERo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
CERo Therapeutics	N/A	N/A	-209.40%

Insider & Institutional Ownership

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Tonix Pharmaceuticals and CERo Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11 million	14.77	-$124.02 million	($14.36)	-0.85
CERo Therapeutics	N/A	N/A	-$8.30 million	($71.01)	0.00

CERo Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Tonix Pharmaceuticals beats CERo Therapeutics on 9 of the 14 factors compared between the two stocks.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company’s rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.